Skip to main content
TipRanks
Go Ultimate75% OFF

Mark Erlander Insider Profile

4 Followers

Mark Erlander, CEO, Director at Cardiff Oncology, holds 24.48K shares in Cardiff Oncology (Ticker: CRDF). Most recently, Mark Erlander Bought 10,000 shares of Cardiff Oncology on Nov 29, 2022 for an estimated value of $14.30K.

Mark Erlander's Trading History

CRDF
Cardiff Oncology
Nov 29, 2022CEO, DirectorInformative Buy14.30K$17.77K
CRDF
Insider Shares: 24.48K (0.05%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Nov 29, 2022Informative Buy$14.30K10,000$1.43-17.10%
Mar 23, 2021Informative Buy$9.98K965$10.34-75.60%
May 18, 2020Informative Buy$10.00K6,993$1.43+371.00%
Jan 03, 2020Uninformative Buy$181.25145$1.25―
Jan 03, 2020Uninformative Buy$865.52698$1.24―

You May Also Like

Mark Erlander insider profile FAQ

What is the percentage of profitable transactions made by Mark Erlander?
The percentage of profitable transactions made by Mark Erlander is 25%.
What is the average return per transaction made by Mark Erlander?
The average return per transaction made by Mark Erlander is 47.70%.
What stocks does Mark Erlander hold?
Mark Erlander holds: CRDF stocks.
What was Mark Erlander’s latest transaction?
Mark Erlander’s latest transaction was an Informative Buy of $14.30K.
What was Mark Erlander's most profitable transaction?
Mark Erlander’s most profitable transaction was an Informative Buy of CRDF stock on May 18, 2020. The return on the trade was 371.00%.
What is Mark Erlander's role in Cardiff Oncology?
Mark Erlander's role in Cardiff Oncology is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.